Aytu BioPharma Shares Outstanding 2008-2021 | AYTU

Aytu BioPharma shares outstanding from 2008 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Aytu BioPharma Annual Shares Outstanding
(Millions of Shares)
2021 17
2020 5
2019 1
2018 0
2017 0
2016 0
2015 0
2014 0
2014 0
2013 0
2012 0
2011 0
2010 0
2009 0
2008 0
2008
2007 0
2007
Aytu BioPharma Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 26
2021-06-30 17
2021-03-31 18
2020-12-31 13
2020-09-30 12
2020-06-30 5
2020-03-31 4
2019-12-31 2
2019-09-30 2
2019-06-30 1
2019-03-31 1
2018-12-31 1
2018-09-30 0
2018-06-30 0
2018-03-31 0
2017-12-31 0
2017-09-30 0
2017-06-30 0
2017-03-31 0
2016-12-31 0
2016-09-30 0
2016-06-30 0
2016-03-31 0
2015-12-31 0
2015-09-30 0
2015-06-30 0
2015-03-31 0
2015-02-28 0
2014-12-31 0
2014-11-30 0
2014-09-30 0
2014-08-31 0
2014-06-30 0
2014-05-31 0
2014-03-31 0
2014-02-28 0
2013-11-30 0
2013-08-31 0
2013-05-31 0
2013-02-28 0
2012-11-30 0
2012-08-31 0
2012-05-31 0
2012-02-29 0
2011-11-30 0
2011-08-31 0
2011-05-31 0
2011-02-28 0
2010-11-30 0
2010-08-31 0
2010-05-31 0
2010-02-28 0
2009-11-30 0
2009-08-31 0
2009-05-31 0
2009-02-28 0
2008-11-30 0
2008-08-31 0
2008-05-31 0
2008-02-29 0
2007-11-30 0
2007-08-31
2007-05-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.036B $0.066B
Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75